First-line Therapy of Stage IV Colorectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

December 31, 2012

Conditions
Stage IV Colorectal Cancer
Interventions
DRUG

Oxaliplatin, Capecitabine, Bevacizumab, Imatinib

"Dose level I:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 100 mg/m2 Capecitabine days 1-14 bid: 800 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22.~Dose level II:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 130 mg/m2 Capecitabine days 1-14 bid: 1000 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22."

Trial Locations (8)

45659

Prosper-Hospital, Recklinghausen

50937

Medical Clinic for Haematology and Oncology, Cologne

55131

Johannes-Gutenberg-Universität Mainz, Mainz

68167

Klinikum Mannheim, Mannheim

73730

Städische Kliniken Esslingen, Esslingen am Neckar

89081

Universitätsklinik Ulm, Ulm

97422

Leopoldina Krankenhaus, Schweinfurt

04129

Klinikum St. Georg gGmbH, Leipzig

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

collaborator

Novartis

INDUSTRY

collaborator

Sanofi

INDUSTRY

lead

University of Cologne

OTHER

NCT00784446 - First-line Therapy of Stage IV Colorectal Cancer | Biotech Hunter | Biotech Hunter